--- title: MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines description: MRNA, the genetic material used in Pfizer and Moderna's COVID-19 vaccines, could also be used to create a new class of drugs and therapies. canonical: https://time.com/6080127/crispr-mrna/ author: Jamie Ducharme article:opinion: false article:content_tier: free article:published_time: 2021-08-02T11:00:32.000Z article:modified_time: 2026-10-14T09:13:48.694Z article:section: Health og:title: mRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines og:description: It could be used to create a host of new drugs og:url: https://time.com/6080127/crispr-mrna/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt610915659f9e2e12/698a1b788fd2eeeb09362c28/mRNA-molecule.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2000 og:image:height: 1125 og:image:alt: Ribosome translating messenger RNA into a polypeptide chain og:type: article twitter:card: summary_large_image twitter:title: mRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines twitter:description: It could be used to create a host of new drugs twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt610915659f9e2e12/698a1b788fd2eeeb09362c28/mRNA-molecule.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=1328f9f3-ee7b-4650-97fd-e8badcf7621b&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=1328f9f3-ee7b-4650-97fd-e8badcf7621b&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=1328f9f3-ee7b-4650-97fd-e8badcf7621b&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=1328f9f3-ee7b-4650-97fd-e8badcf7621b&cr=time-nl-network-2026q3-v1) ## Video: MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines [Watch (HLS stream): MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines](https://cdn.jwplayer.com/manifests/5Xw1wUiA.m3u8) (2:24)  _Published 2021-08-01. The tremendous efficacy of mRNA-based COVID-19 vaccines has generated plenty of excitement about its potential use in vaccines for other diseases. And vaccines may be just the beginning._  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Aug 2, 2021 11:00 AM UTC The tremendous efficacy of mRNA-based COVID-19 vaccines has generated plenty of excitement about its potential use in vaccines for other diseases. And vaccines may be just the beginning.  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Aug 2, 2021 11:00 AM UTC It’s safe to say that before the development of the [Pfizer-BioNTech](https://time.com/collection/coronavirus-vaccines-updates/5926234/pfizer-biontech-covid-19-vaccine/) and [Moderna](https://time.com/collection/coronavirus-vaccines-updates/5926241/moderna-covid-19-vaccine/) COVID-19 vaccines, most people hadn’t thought about messenger RNA, or mRNA, since high school science class—if ever. The molecule plays a pivotal role in the body, carrying the recipes for making various proteins to the parts of cells that produce them. But “mRNA” wasn’t exactly a common phrase until Pfizer-BioNTech and Moderna harnessed the genetic material’s power to teach the body to make a piece of a protein found on the COVID-19 virus’ surface, thus training it to fight the real thing, were it to attack. The tremendous [efficacy of mRNA-based COVID-19 vaccines](https://time.com/5945177/covid-19-vaccine-effectiveness/) has generated plenty of excitement about its potential use in [vaccines for other diseases](https://www.nature.com/articles/s41591-021-01393-8). And vaccines may be just the beginning. Last month, researchers used mRNA to deliver CRISPR gene-editing technology that could permanently treat a rare genetic disease in humans—an advance that experts say has implications far beyond the treatment of a single condition. Medical science research utilizing CRISPR—[a system](https://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/) that allows scientists to add, remove or change specific genetic information within the body—had already been advancing rapidly in recent years. Researchers have shown its potential for reversing [blindness](https://www.nature.com/articles/d41586-020-00655-8) and [sickle cell anemia](https://news.berkeley.edu/2021/03/30/fda-approves-first-test-of-crispr-to-correct-genetic-defect-causing-sickle-cell-disease/), and to treat genetic diseases [in animals](https://www.genengnews.com/topics/translational-medicine/crispr-reverses-disease-symptoms-in-living-animals-for-first-time/). But new work [described](https://www.nejm.org/doi/full/10.1056/NEJMoa2107454) in the _New England Journal of Medicine_ in June marks what researchers are calling the first time CRISPR has been shown to treat a genetic disorder when directly administered to human patients. In this case, the technology was applied towards a therapy for transthyretin amyloidosis, a genetic disease that causes sufferers’ livers to produce a protein that eventually builds up to toxic levels. The [disease’s prevalence](https://medlineplus.gov/genetics/condition/transthyretin-amyloidosis/#:~:text=The%20exact%20incidence%20of%20transthyretin,affect%20one%20in%20100%2C000%20people.) varies depending on patient demographics—it affects about one in 100,000 Americans of European descent, but as many as one in every 538 people in northern Portugal, for example—and can be passed down to future generations. While there are drugs that can help patients manage the disease, the goal of the new research was to stop the problem at its source. “To imagine using \[CRISPR\] as a therapy for people, you need to figure out how to get these editing tools into the cells you’re trying to fix. That’s where messenger RNA comes in,” explains Daniel Anderson, a professor of chemical engineering at the Massachusetts Institute of Technology and a co-founder of CRISPR Therapeutics, which uses CRISPR technology to develop medications. Anderson was not involved in the research. The research team, led by Dr. Julian Gillmore, an amyloidosis expert at the U.K.’s Royal Free Hospital, programmed mRNA to deliver gene-editing instructions to the liver, shutting down the part responsible for producing the toxic protein. After a one-time injection of the drug, three of the six people in the trial saw an almost complete drop-off in protein production; the remaining three, who received a smaller dose, saw less dramatic results. It will take a few months to see if that accomplishment translates to symptom relief, but the early findings are promising. (The work was funded by pharmaceutical companies Intellia Therapeutics and Regeneron, which produce the injectable CRISPR drug.) As Dr. John Leonard, Intellia’s president and CEO, puts it: “mRNA is a way to make CRISPR gene editing come alive. CRISPR is the workhorse; mRNA encodes it.” In theory, the same general technology could be used to treat conditions beyond transthyretin amyloidosis. “There are a host of diseases in the liver where this might work in an analogous manner,” says Dr. Kenneth Chien, a senior professor of cardiology research at Sweden’s Karolinska Institutet and a co-founder of Moderna Therapeutics, who was not involved in the research. “The most important aspect of this is the implications that the technology can be repurposed.” Chien has believed in mRNA’s drug-development potential for more than a decade. When Moderna was founded in 2010, in fact, its chief goal was to develop mRNA-based drugs, not vaccines. (Chien no longer works at Moderna and is now an advisor to the pharmaceutical giant AstraZeneca.) He continues to work on an mRNA-based drug he hopes could eventually treat heart conditions. The tricky part, Leonard says, is figuring out how to get a drug into different tissues, since the strategy for delivering CRISPR-based therapeutics varies depending on its target. The new research offers a blueprint for liver-based conditions, and Leonard believes similar approaches could be used in the near-term for bone-marrow, nervous-system and muscle diseases. The list theoretically grows from there, so long as researchers can fine-tune delivery. “COVID \[vaccines are\] a big success for mRNA, and if it does nothing else, it’s been great,” Chien says. “However, I think you’re going to see the next chapter of mRNA is going to be as exciting, if not more so, than the story of mRNA vaccines.” ## Transcript [00:00] The Royal Swedish Academy of Sciences has today decided to award [00:04] the 2020 Nobel Prize in chemistry joint, [00:09] you to remind Jennifer doudna for the development of a method [00:15] for genome editing Muscular Dystrophy, and even HIV in the crisper [00:24] cast. Nine system was an important advance in the Nobel Prize [00:27] was recently, awarded for its Discovery in use some genome-editing, [00:31] but to imagine using this as a therapy for people, [00:35] you need to figure out how to get these editing tools inside [00:38] of the cells. [00:39] You're trying to fix [00:40] And that's where messenger-rna comes in. [00:49] Messenger RNA is part of a actually a large class of of different [00:54] RNA. Drugs that can be used to turn genes on as in the case [01:00] of the vaccine when we were basically delivery and an antigen [01:02] stimulate immunity sponsor, a messenger RNA vaccine efficacy [01:10] of lowering a small rnas that can actually silence genes to suppress [01:17] for the treatment of disease and then now with Christopher [01:23] and other genome editing tools, we can think about permanently [01:26] changing jeans to turn them on or turn them off. [01:42] You can deliver messenger-rna inside of the cells are trying [01:46] to treat. Then you can create a genome editing complex that [01:49] can then go in and actually fix the DNA. [01:52] The covid vaccine experience has really brought awareness [01:57] of the potential of messenger. [01:58] RNA has a drug to be developed quickly and have real impact [02:01] the dream that you can build these nanoparticles to create. [02:05] Therapeutics genetic events is becoming more and more clear. [02:09] The potential is there. [02:11] And you know the fact that you can do it for 1 to see [02:14] you skipped you hope you can use it for other diseases as well. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6080127/crispr-mrna/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6080127/crispr-mrna/"},"headline":"MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines","datePublished":"2021-08-02T11:00:32.000Z","dateModified":"2026-10-14T09:13:48.694Z","description":"MRNA, the genetic material used in Pfizer and Moderna's COVID-19 vaccines, could also be used to create a new class of drugs and therapies.","url":"https://time.com/6080127/crispr-mrna/","keywords":["Innovation","medicine","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt610915659f9e2e12/698a1b788fd2eeeb09362c28/mRNA-molecule.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Jamie Ducharme","jobTitle":"Ducharme is a contributor to TIME.","url":"https://time.com/author/jamie-ducharme/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt610915659f9e2e12/698a1b788fd2eeeb09362c28/mRNA-molecule.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Ribosome translating messenger RNA into a polypeptide chain","caption":"Ribosome translating messenger RNA into a polypeptide chain","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/innovation/","name":"Innovation"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6080127/crispr-mrna/","name":"MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines","description":"The tremendous efficacy of mRNA-based COVID-19 vaccines has generated plenty of excitement about its potential use in vaccines for other diseases. And vaccines may be just the beginning.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/5Xw1wUiA/poster.jpg?width=720","uploadDate":"2021-08-01T17:23:00.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/5Xw1wUiA.m3u8","embedUrl":"https://time.com/6080127/crispr-mrna/","duration":"PT2M24S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/6080127/crispr-mrna/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```